Weill Medical College Of Cornell University

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private, Subsidiary

Established: 1865-01-01

Employees: -

Market Cap: -

Website: http://weill.cornell.edu

Clinical Trials

Study of Decadron, Biaxin, and Pomalidomide in Relapsed/Refractory Myeloma

Phase 2

Completed

Conditions: Multiple Myeloma

Interventions: Drug: dexamethasone
Drug: clarithromycin
Drug: Pomalidomide

First Posted Date: 2010-07-09

Last Posted Date: 2019-06-11

Lead Sponsor: Weill Medical College of Cornell University

Target Recruit Count: 121

Registration Number: NCT01159574

Locations: 🇺🇸
Weill Cornell Medical College, New York, New York, United States

Combination Veltuzumab and Fractionated 90Y- Epratuzumab Radioimmunotherapy in Follicular Lymphoma

Phase 1

Terminated

Conditions: Follicular Lymphoma

Interventions: Drug: 90Y-epratuzumab tetraxetan
Biological: veltuzumab

First Posted Date: 2010-06-22

Last Posted Date: 2018-02-22

Lead Sponsor: Weill Medical College of Cornell University

Target Recruit Count: 4

Registration Number: NCT01147393

Locations: 🇺🇸
Weill Cornell Medical College, New York, New York, United States

Trial of Three Stem Cell Mobilization Regimens for Multiple Myeloma

Phase 3

Completed

Conditions: Multiple Myeloma

Interventions: Drug: bortezomib (Velcade)
Drug: cyclophosphamide
Drug: Plerixafor
Drug: G-CSF

First Posted Date: 2010-06-22

Last Posted Date: 2019-12-27

Lead Sponsor: Weill Medical College of Cornell University

Target Recruit Count: 47

Registration Number: NCT01146834

Locations: 🇺🇸
Memorial Sloan-Kettering Cancer Center):, New York, New York, United States
🇺🇸
Emory University, Atlanta, Georgia, United States
🇺🇸
New York University Cancer Institute, New York, New York, United States

and more 2 locations

Assessing the Impact of Health Information Exchange (HIE) on Healthcare Utilization

Completed

Conditions: Health Care Utilization
Health Information Technology
Health Information Exchange
Virtual Health Record

Interventions: Other: Virtual Health Record (VHR)

First Posted Date: 2010-06-22

Last Posted Date: 2018-08-21

Lead Sponsor: Weill Medical College of Cornell University

Target Recruit Count: 218766

Registration Number: NCT01147328

Locations: 🇺🇸
HealtheLink, Buffalo, New York, United States
🇺🇸
Rochester RHIO, Rochester, New York, United States
🇺🇸
Weill Medical College of Cornell University, New York, New York, United States

Alternating Thalidomide and Lenalidomide Therapy Plus Rituximab (ThRiL) as Initial Treatment for Patients With CLL

Phase 2

Completed

Conditions: Chronic Lymphocytic Leukemia

Interventions: Drug: thalidomide
Drug: lenalidomide
Biological: rituximab

First Posted Date: 2010-05-18

Last Posted Date: 2022-01-21

Lead Sponsor: Weill Medical College of Cornell University

Target Recruit Count: 15

Registration Number: NCT01125176

Locations: 🇺🇸
Weill Cornell Medical College, New York, New York, United States

Treatment of Polycythemia Vera With Gleevec

Phase 2

Completed

Conditions: Polycythemia Vera

Interventions: Drug: Gleevec

First Posted Date: 2010-05-11

Last Posted Date: 2010-05-17

Lead Sponsor: Weill Medical College of Cornell University

Target Recruit Count: 36

Registration Number: NCT01120821

Locations: 🇺🇸
Weill Cornell Medical College, New York, New York, United States

Study of 5-azacitidine in Combination With Vorinostat in Patients With Relapsed or Refractory Diffuse Large b Cell Lymphoma (DLBCL)

Phase 1

Completed

Conditions: Lymphoma

Interventions: Drug: azacytidine
Drug: vorinostat

First Posted Date: 2010-05-11

Last Posted Date: 2017-04-10

Lead Sponsor: Weill Medical College of Cornell University

Target Recruit Count: 17

Registration Number: NCT01120834

Locations: 🇺🇸
Weill Cornell Medical College, New York, New York, United States

Trial of PD 0332991 Plus Bortezomib in Patients With Relapsed Mantle Cell Lymphoma

Phase 1

Terminated

Conditions: Mantle Cell Lymphoma

Interventions: Drug: PD 0332991
Drug: bortezomib

First Posted Date: 2010-04-27

Last Posted Date: 2019-06-27

Lead Sponsor: Weill Medical College of Cornell University

Target Recruit Count: 20

Registration Number: NCT01111188

Locations: 🇺🇸
Weill Cornell Medical College, New York, New York, United States

Engaging Depressed Low-Income Seniors in Mental Health Services

Not Applicable

Completed

Conditions: Depression

Interventions: Behavioral: ENGAGE

First Posted Date: 2010-03-29

Last Posted Date: 2017-11-08

Lead Sponsor: Weill Medical College of Cornell University

Target Recruit Count: 12

Registration Number: NCT01094951

SOD1 Inhibition by Pyrimethamine in Familial Amyotrophic Lateral Sclerosis (ALS)

Phase 1

Completed

Conditions: Familial Amyotrophic Lateral Sclerosis

Interventions: Drug: Pyrimethamine

First Posted Date: 2010-03-10

Last Posted Date: 2017-06-19

Lead Sponsor: Weill Medical College of Cornell University

Target Recruit Count: 32

Registration Number: NCT01083667

Locations: 🇩🇪
Universitäts- und Rehabilitationskliniken Ulm, Ulm, Germany
🇺🇸
Methodist Neurological Institute, Houston, Texas, United States
🇺🇸
Weill Cornell Medical Center/New York Presbyterian Hospital, New York, New York, United States

and more 2 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy